January 31, 2015 8:19 PM ET

Capital Markets

Company Overview of The Column Group LLC

Executive Profile

Roger M. Perlmutter M.D., Ph.D.

Executive Vice President and President of Merck Research Laboratories, Merck & Co. Inc.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 8 different industries.

See Board Relationships
62$5,986,124
As of Fiscal Year 2013

Background

Dr. Roger M. Perlmutter, M.D., Ph.D. has been the Executive Vice President and President of Merck Research Laboratories at Merck & Co. Inc. since April 15, 2013. Dr. Perlmutter serves as Science Partner at The Column Group LLC. Dr. Perlmutter was a Professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington in Seattle from January 1991 to January 1997. From 1981 to 1984, he was a Lecturer in the Division of Biology at the California ...

Corporate Headquarters

1700 Owens Street
San Francisco, California 94158

United States

Phone: 415-865-2050
Fax: 415-255-2048

Board Members Memberships

Director
2000-2013
Former Director and Member of Corporate Governance & Nominating Committee
2012-2013
Former Director
2012-Present
Non-Executive Director
2012-N/A
Former Director and Member of Scientific Advisory Board

Education

PhD 1979
Washington University, St. Louis
MD 1979
Washington University, St. Louis
Unknown/Other Education 1973
Reed College

Other Affiliations

Annual Compensation

Salary$711,538
Bonus$500,000
Total Annual Compensation$1,211,538

Stocks Options

Restricted Stock Awards$2,699,987
All Other Compensation$16,459
Unexercisable Options$225,443
Unexercisable Options Value$1,142,996
Total Value of Options$1,142,996
Total Number of Options$225,443

Total Compensation

Total Annual Cash Compensation$1,851,697
Total Short Term Compensation$1,211,538
Other Long Term Compensation$2,716,446
Total Calculated Compensation$5,986,124
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
$2.9M
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
$2.9M
Serge Weinberg Chairman, Interim Chief Executive Officer, Chairman of Appointments & Governance Committee and Chairman of Strategy Committee
Sanofi
$700.0K
Severin Schwan Ph.D.Chief Executive Officer and Director
Roche Holding AG
$5.1M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Column Group LLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.